MedTrace Logo

Biking vs. Running: Comparison of EPOC, Substrate Oxidation, Appetite and Energy Intakes in Men With Overweight/Obesity.

NCT06082310 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2023-12-11

No results posted yet for this study

Summary

The management of obesity involves hygienic and dietary measures that include appropriate nutrition and an increase in physical activity (PA). Among the various PA modalities that can be recommended, High-Intensity Interval Training (HIIT) is now recognized as a fun and effective program for promoting fat loss. A meta-analysis conducted by our team suggests a potential influence of the mode of HIIT practice (cycling vs. running) on fat mass (FM) loss. In order to better understand the metabolic adaptations following this type of practice, the investigators propose to compare two isoenergetic HIIT sessions (cycling vs. running) in overweight or obese subjects. The objective is to compare post-recovery (+2h) oxygen consumption, substrate utilization, concurrent energy expenditure and post 24h energy intakes.

Conditions

  • Overweight and Obesity

Interventions

OTHER

Exercise

Two HIIT modalities

Sponsors & Collaborators

  • CREPS Auvergne-Rhône-Alpes de Vichy

    collaborator UNKNOWN

  • Laboratoire des Adaptations Métaboliques à l'Exercice en conditions Physiologiques et Pathologiques

    lead OTHER

Principal Investigators

  • Claire Morel, Dr · CREPS Auvergne Rhône-Alpes / Vichy

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-01-11
Primary Completion
2023-12-08
Completion
2023-12-08

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06082310 on ClinicalTrials.gov